Innocan Pharma Corporation announced the successful results of a controlled efficacy trial (the "Trial") of their diabetic foot relief cream (the "Product"). The Trial results affirm that Innocan's Product - a proprietary formulation of cannabinoids, vasoconstriction stimulators, and potent moisturizers - is highly effective in alleviating foot dryness and decreasing the risk of skin cracking, a precursor to bruising and subsequent diabetic complications in individuals with diabetes. The seven-day Trial involved a diverse group of male and female volunteers living with diabetes and suffering from dry skin.

The Trial's primary benchmark - a statistically significant reduction in foot dryness - was achieved through enhanced skin hydration and a notable decrease in epidermal water loss, with improvements visible within one hour, and sustained over the entire week-long Trial. Furthermore, 97% of the Trial volunteers reported an immediate amelioration in foot skin dryness, 97% noted increased foot skin hydration, 90% observed their foot skin to be more elastic, and 97% would recommend the product to peers. Through the application of cannabinoids and other natural ingredients, Innocan offers a viable, healthy alternative for diabetic patients aiming for immediate protection from skin dryness, crack formation, and the risk of subsequent complications.

The global diabetic foot ulcer treatment market was valued at USD 8.6 billion in 2021 and is projected to reach approximately USD 14.8 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.22% from 2022 to 2030.